2Manzoni P,Riz2011o S,Mostert M,et al.Preeclampsia,neutropenia,and risk of fungal sepsis in preterm very low birth weight infants[J].J Pediatr,2011,158(1):173-174.
3Pagano L,Akova M,Dimopoulos G,et al.Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients[J].J Antimicrob Chemother,2011(1):i5-14.
4Unsinger J,Burnham CA,McDonough J,et al.Interleukin-7ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis[J].J Infect Dis,2012,206(4):606-616.
5Hahn-Ast C,Glasmacher A,Mückter S,et al.Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995to 2006[J].J Antimicrob Chemother,2010,65(4):761-768.
6Freifeld AG,Bow EJ,Sepkowitz KA,et al.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010update by the infectious diseases society of America[J].Clin Infect Dis,2011,52(4):e56-93.
7Zabalza A,Gorosquieta A,Equiza EP,et al.Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies:aperspective review[J].Ther Adv Hematol,2013,4(3):217-230.
8Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained:a potential risk factor for hospital mortality. Antimicrob Agents Chemother, 2005, 49(9):3640-3645.
